Cyclerion Change In Cash from 2010 to 2024

CYCN Stock  USD 6.35  4.74  294.41%   
Cyclerion Therapeutics Change In Cash yearly trend continues to be very stable with very little volatility. Change In Cash is likely to grow to about -5.5 M this year. During the period from 2010 to 2024, Cyclerion Therapeutics Change In Cash quarterly data regression pattern had range of 147 M and standard deviation of  60,880,238. View All Fundamentals
 
Change In Cash  
First Reported
2018-03-31
Previous Quarter
-1.1 M
Current Value
-1.7 M
Quarterly Volatility
50.7 M
 
Covid
Check Cyclerion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclerion Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 355 K or Selling General Administrative of 16.2 M, as well as many indicators such as Price To Sales Ratio of 90.71, Dividend Yield of 0.0 or PTB Ratio of 0.73. Cyclerion financial statements analysis is a perfect complement when working with Cyclerion Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cyclerion Therapeutics Correlation against competitors.
To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.

Latest Cyclerion Therapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Cyclerion Therapeutics over the last few years. It is Cyclerion Therapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclerion Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Slightly volatile
   Change In Cash   
       Timeline  

Cyclerion Change In Cash Regression Statistics

Arithmetic Mean61,709,303
Coefficient Of Variation98.66
Mean Deviation54,548,929
Median102,621,000
Standard Deviation60,880,238
Sample Variance3706.4T
Range147M
R-Value(0.78)
Mean Square Error1531.9T
R-Squared0.62
Significance0.0005
Slope(10,686,358)
Total Sum of Squares51889.6T

Cyclerion Change In Cash History

2024-5.5 M
2023-5.8 M
2022-40.6 M
2021-4.3 M
2020-44.4 M

About Cyclerion Therapeutics Financial Statements

Cyclerion Therapeutics investors utilize fundamental indicators, such as Change In Cash, to predict how Cyclerion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Cash-5.8 M-5.5 M

Pair Trading with Cyclerion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cyclerion Stock

  0.62ME 23Andme HoldingPairCorr
  0.81VALN Valneva SE ADRPairCorr

Moving against Cyclerion Stock

  0.77VCYT VeracytePairCorr
  0.68VCEL Vericel Corp OrdPairCorr
  0.63VERA Vera TherapeuticsPairCorr
  0.49SABSW SAB BiotherapeuticsPairCorr
  0.45VANI Vivani MedicalPairCorr
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:
Check out the analysis of Cyclerion Therapeutics Correlation against competitors.
To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
0.586
Quarterly Revenue Growth
0.141
Return On Assets
(0.47)
Return On Equity
(1.50)
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.